Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07287137
PHASE4

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

View on ClinicalTrials.gov

Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Official title: IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2025-11-12

Completion Date

2027-09

Last Updated

2026-05-04

Healthy Volunteers

Yes

Interventions

DRUG

Pfizer-BioNTech mRNA COVID-19 vaccine

COVID-19 Vaccine, mRNA

DRUG

Novavax recombinant protein vaccine

Recombinant protein vaccine

Locations (1)

Walter Reed National Military Medical Center

Bethesda, Maryland, United States